Get the Stockscreener App
431.66
0.84%
-3.44
Vertex Pharmaceuticals Inc stock is traded at $431.66, with a volume of 509.68K.
It is down -0.84% in the last 24 hours and down -3.83% over the past month.
Vertex Pharmaceuticals is a global biotechnology company that discovers and develops small-molecule drugs for the treatment of serious diseases. Its key drugs are Kalydeco, Orkambi, Symdeko, and Trikafta/Kaftrio, and Alyftrek for cystic fibrosis, where Vertex therapies remain the standard of care globally. Vertex has diversified its portfolio through Casgevy, a gene-editing therapy for beta thalassemia and sickle-cell disease, and Journavx, a non-opioid pain medication approved for the treatment of moderate-to-severe acute pain in adults. Additionally, Vertex is evaluating small-molecule inhibitors of APOL1-mediated kidney diseases. Vertex is also investigating cell therapies to deliver a potential functional cure for type 1 diabetes.
See More
Previous Close:
$435.10
Open:
$431.89
24h Volume:
509.68K
Relative Volume:
0.37
Market Cap:
$109.77B
Revenue:
$12.07B
Net Income/Loss:
$3.95B
P/E Ratio:
28.15
EPS:
15.3349
Net Cash Flow:
$3.19B
1W Performance:
-2.21%
1M Performance:
-3.83%
6M Performance:
+2.39%
1Y Performance:
-12.39%
1-Day Range:
$427.38
$433.68
1-Week Range:
$427.38
$444.01
52-Week Range:
$362.50
$510.77
Vertex Pharmaceuticals Inc Stock (VRTX) Company Profile
Name
Vertex Pharmaceuticals Inc
Sector
Industry
Phone
(617) 341-6393
Address
50 NORTHERN AVENUE, BOSTON, MA
Compare VRTX vs REGN, ARGX, ALNY, ONC
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
VRTX
Vertex Pharmaceuticals Inc
|
431.54 | 110.67B | 12.07B | 3.95B | 3.19B | 15.33 |
REGN
Regeneron Pharmaceuticals Inc
|
745.45 | 80.98B | 14.34B | 4.50B | 3.77B | 41.56 |
ARGX
Argen X Se Adr
|
779.91 | 49.00B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
303.96 | 41.87B | 3.71B | 313.75M | 465.38M | 2.2571 |
ONC
Beone Medicines Ltd Adr
|
300.28 | 33.28B | 5.36B | 287.73M | 924.18M | 2.5229 |
Vertex Pharmaceuticals Inc Stock (VRTX) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Mar-18-26 | Upgrade | Maxim Group | Hold → Buy |
| Mar-10-26 | Initiated | Jefferies | Buy |
| Mar-10-26 | Reiterated | Oppenheimer | Outperform |
| Feb-13-26 | Upgrade | Oppenheimer | Perform → Outperform |
| Jan-28-26 | Resumed | Barclays | Overweight |
| Jan-22-26 | Upgrade | RBC Capital Mkts | Sector Perform → Outperform |
| Jan-12-26 | Upgrade | Bernstein | Mkt Perform → Outperform |
| Jan-07-26 | Resumed | UBS | Buy |
| Jan-06-26 | Upgrade | Wolfe Research | Peer Perform → Outperform |
| Dec-03-25 | Upgrade | Morgan Stanley | Equal-Weight → Overweight |
| Nov-13-25 | Initiated | Scotiabank | Sector Outperform |
| Sep-25-25 | Upgrade | Leerink Partners | Market Perform → Outperform |
| Sep-03-25 | Initiated | Raymond James | Mkt Perform |
| Aug-06-25 | Upgrade | Wells Fargo | Equal Weight → Overweight |
| May-07-25 | Downgrade | Wolfe Research | Outperform → Peer Perform |
| May-06-25 | Downgrade | Leerink Partners | Outperform → Market Perform |
| Apr-22-25 | Resumed | Cantor Fitzgerald | Overweight |
| Feb-12-25 | Upgrade | Canaccord Genuity | Sell → Hold |
| Feb-11-25 | Upgrade | Canaccord Genuity | Sell → Hold |
| Jan-30-25 | Downgrade | Wells Fargo | Overweight → Equal Weight |
| Dec-20-24 | Reiterated | H.C. Wainwright | Buy |
| Dec-19-24 | Downgrade | Oppenheimer | Outperform → Perform |
| Dec-09-24 | Upgrade | Jefferies | Hold → Buy |
| Nov-14-24 | Initiated | Citigroup | Buy |
| Oct-16-24 | Initiated | Scotiabank | Sector Perform |
| Oct-10-24 | Resumed | Raymond James | Mkt Perform |
| Aug-05-24 | Downgrade | Barclays | Overweight → Equal Weight |
| Jun-27-24 | Initiated | Redburn Atlantic | Buy |
| Apr-11-24 | Upgrade | Evercore ISI | In-line → Outperform |
| Feb-15-24 | Initiated | Wolfe Research | Outperform |
| Feb-06-24 | Downgrade | Evercore ISI | Outperform → In-line |
| Feb-02-24 | Downgrade | Bernstein | Outperform → Mkt Perform |
| Jan-31-24 | Downgrade | Maxim Group | Buy → Hold |
| Jan-31-24 | Downgrade | Robert W. Baird | Neutral → Underperform |
| Jan-24-24 | Downgrade | Canaccord Genuity | Hold → Sell |
| Dec-14-23 | Reiterated | RBC Capital Mkts | Sector Perform |
| May-30-23 | Initiated | William Blair | Outperform |
| May-04-23 | Resumed | Piper Sandler | Overweight |
| Mar-21-23 | Initiated | Bernstein | Outperform |
| Jan-18-23 | Initiated | Canaccord Genuity | Hold |
| Jan-17-23 | Upgrade | SVB Leerink | Mkt Perform → Outperform |
| Dec-19-22 | Downgrade | Jefferies | Buy → Hold |
| Jul-13-22 | Initiated | Cantor Fitzgerald | Overweight |
| Jun-01-22 | Upgrade | Maxim Group | Hold → Buy |
| May-23-22 | Initiated | SVB Leerink | Mkt Perform |
| May-06-22 | Downgrade | Robert W. Baird | Outperform → Neutral |
| May-03-22 | Upgrade | Morgan Stanley | Underweight → Equal-Weight |
| Feb-03-22 | Downgrade | RBC Capital Mkts | Outperform → Sector Perform |
| Jan-27-22 | Reiterated | JP Morgan | Overweight |
| Jan-27-22 | Reiterated | Morgan Stanley | Underweight |
| Jan-27-22 | Reiterated | RBC Capital Mkts | Outperform |
| Jan-27-22 | Reiterated | Stifel | Hold |
| Jan-27-22 | Reiterated | Wolfe Research | Outperform |
| Jan-20-22 | Upgrade | BMO Capital Markets | Market Perform → Outperform |
| Dec-09-21 | Initiated | Wells Fargo | Overweight |
| Nov-19-21 | Initiated | BMO Capital Markets | Market Perform |
| Nov-19-21 | Downgrade | Piper Sandler | Overweight → Neutral |
| Sep-09-21 | Downgrade | Stifel | Buy → Hold |
| Sep-07-21 | Downgrade | Morgan Stanley | Equal-Weight → Underweight |
| Jul-20-21 | Downgrade | SVB Leerink | Mkt Perform → Underperform |
| Jul-19-21 | Resumed | Wolfe Research | Outperform |
| Jul-01-21 | Initiated | Raymond James | Mkt Perform |
| Jun-11-21 | Downgrade | Daiwa Securities | Outperform → Neutral |
| Feb-23-21 | Upgrade | Robert W. Baird | Neutral → Outperform |
| Feb-02-21 | Reiterated | H.C. Wainwright | Buy |
| Dec-30-20 | Initiated | Daiwa Securities | Outperform |
| Nov-30-20 | Upgrade | RBC Capital Mkts | Sector Perform → Outperform |
| Nov-20-20 | Initiated | Bernstein | Outperform |
| Oct-28-20 | Initiated | UBS | Buy |
| Jul-31-20 | Reiterated | H.C. Wainwright | Buy |
| Jul-08-20 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| Apr-30-20 | Reiterated | H.C. Wainwright | Buy |
| Apr-28-20 | Downgrade | RBC Capital Mkts | Outperform → Sector Perform |
| Mar-04-20 | Initiated | Barclays | Overweight |
| Jan-31-20 | Downgrade | Robert W. Baird | Outperform → Neutral |
| Nov-19-19 | Upgrade | Guggenheim | Neutral → Buy |
| Nov-12-19 | Initiated | SunTrust | Buy |
| Oct-17-19 | Resumed | BofA/Merrill | Buy |
| Sep-03-19 | Upgrade | Goldman | Neutral → Buy |
| Aug-01-19 | Downgrade | Needham | Buy → Hold |
| May-23-19 | Resumed | Citigroup | Buy |
| May-21-19 | Initiated | Credit Suisse | Outperform |
| Apr-12-19 | Initiated | Evercore ISI | In-line |
| Mar-26-19 | Upgrade | William Blair | Mkt Perform → Outperform |
| Mar-19-19 | Downgrade | SVB Leerink | Outperform → Mkt Perform |
| Feb-06-19 | Downgrade | Maxim Group | Buy → Hold |
View All
Vertex Pharmaceuticals Inc Stock (VRTX) Latest News
Vertex Pharmaceuticals Incorporated (VRTX) PT Nudged Higher as RBC Updates Biotech Sector Outlook - Yahoo Finance
3 Healthcare Stocks With the Most Durable Competitive Moats - The Motley Fool
Vertex Pharmaceuticals Inc. (VRTX)Bullish Jim Cramer Endorsement Highlights Divergent Sentiment Amid Mixed Pipeline UpdatesAsset Sale - Xã Thanh Hà
Best Biotech Stocks To Watch TodayApril 22nd - MarketBeat
Vertex Pharmaceuticals: Looking For Signs Of Success In Q1 Earnings (NASDAQ:VRTX) - Seeking Alpha
Jim Cramer on Vertex Pharmaceuticals: “I Wish I Had Bought It for the Charitable Trust a Long Time Ago” - Insider Monkey
Morgan Stanley Maintains Vertex Pharmaceuticals(VRTX.US) With Buy Rating, Maintains Target Price $612 - Moomoo
Vertex Pharmaceuticals Incorporated (VRTX) is Attracting Investor Attention: Here is What You Should Know - Yahoo Finance
Halozyme Therapeutics Partners with Vertex for Hypercon Technology - HarianBasis.co
Fierce Biotech Layoff Tracker 2026: Replimune reduces staff; Astellas shutters cell therapy site - Fierce Biotech
Vertex Pharma stock (US92532F1003): Is the cystic fibrosis dominance now unlocking broader upside? - AD HOC NEWS
Vertex Pharma stock (US92532F1003): Is its cystic fibrosis dominance strong enough to unlock new ups - AD HOC NEWS
2 Under-the-Radar Biotech Stocks Worth Buying for the Long Term - The Motley Fool
Vertex Pharmaceuticals Experiences Evaluation Revision Amid Mixed Market Performance Indicators - Markets Mojo
GF Fund Management CO. LTD. Raises Position in Vertex Pharmaceuticals Incorporated $VRTX - MarketBeat
Vertex Pharmaceuticals Incorporated $VRTX Stock Position Lifted by Asset Management One Co. Ltd. - MarketBeat
Morgan Stanley Lifts Vertex Pharmaceuticals (VRTX) PT on Updated Biopharma Models - Insider Monkey
Cramer's lightning round: Buy Vertex Pharmaceuticals - MSN
Lightning round: Buy Vertex Pharmaceuticals - MSN
Lightning Round: Buy Vertex Pharmaceuticals - CNBC
Vertex Pharmaceuticals (VRTX) Beats Stock Market Upswing: What Investors Need to Know - Yahoo Finance
Vertex Pharmaceuticals Inc. stock outperforms competitors on strong trading day - MarketWatch
Vertex (VRTX) director receives new deferred stock unit grant - Stock Titan
VRTX Stock Quote Price and Forecast - CNN
Vertex (NASDAQ: VRTX) director granted 107 deferred stock units as equity pay - Stock Titan
Vertex (VRTX) board member receives deferred stock unit award - Stock Titan
Vertex Pharma stock (US92532F1003): Is cystic fibrosis dominance still enough for long-term upside? - AD HOC NEWS
Vertex Pharmaceuticals Incorporated $VRTX Shares Acquired by Mirae Asset Global Investments Co. Ltd. - MarketBeat
KBC Group NV Acquires 7,518 Shares of Vertex Pharmaceuticals Incorporated $VRTX - MarketBeat
Vertex Pharmaceuticals (VRTX) Stock Slides as Market Rises: Facts to Know Before You Trade - Yahoo Finance
Vertex’s IgAN drug outlook strengthens on positive phase 3 data - S&P Global
Vertex Pharmaceuticals Inc. stock underperforms Thursday when compared to competitors - MarketWatch
Is Vertex Pharmaceuticals' Empire in Trouble? - AOL.com
Vertex Pharmaceuticals Incorporated : 2025 Data Summary - marketscreener.com
Vertex price returns lowerForecast today16-04-2026 - Economies.com
Morgan Stanley Keeps Their Buy Rating on Vertex Pharmaceuticals (VRTX) - The Globe and Mail
Lbp Am Sa Acquires 22,918 Shares of Vertex Pharmaceuticals Incorporated $VRTX - MarketBeat
Vertex Pharmaceuticals Inc (STU:VX1) Stock Price & 30 Year Financial Data - GuruFocus
Vertex Pharmaceuticals: Solid CF Franchise and Emerging Pipeline Support Buy Rating and Premium Valuation - TipRanks
Zealand Pharma appoints US-based investor relations head - medwatch.com
5 biopharma M&A deals where the workforce was the prize - BioSpace
Vertex Sues Former Exec To Block Move To Rival - Law360
Baillie Gifford Trims Vertex Pharmaceuticals Stake - National Today
15,717 Shares in Vertex Pharmaceuticals Incorporated $VRTX Bought by Third View Private Wealth LLC - MarketBeat
Massachusetts Financial Services Co. MA Sells 291,226 Shares of Vertex Pharmaceuticals Incorporated $VRTX - MarketBeat
Baillie Gifford & Co. Has $91.17 Million Stock Position in Vertex Pharmaceuticals Incorporated $VRTX - MarketBeat
Argenx and Vertex Pharmaceuticals named BofA top biotech picks for 2026 - Investing.com UK
Hardman Johnston Global Advisors LLC Sells 15,346 Shares of Vertex Pharmaceuticals Incorporated $VRTX - MarketBeat
Vertex Pharmaceuticals Incorporated $VRTX Shares Bought by Andrew Hill Investment Advisors Inc. - MarketBeat
Sumitomo Mitsui Trust Group Reduces Vertex Pharmaceuticals Stake - National Today
Robeco Institutional Asset Management B.V. Raises Stock Holdings in Vertex Pharmaceuticals Incorporated $VRTX - MarketBeat
Vertex Pharmaceuticals Inc Stock (VRTX) Financials Data
Revenue
Net Income
Cash Flow
EPS
2.72%
0.27%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):